Skip to main content
Livermore
Livermore
ZHEN

Deep Track Capital, LP

SEC CIK
0001856083
Latest filing
Aug 14, 2026

Holdings in Q3 2024

Holdings as of Sep 30, 2024, filed Nov 14, 2024. Long positions only; changes compare share counts with Q2 2024.

Institution overview
Positions
69
+2 vs. Q2 2024
Portfolio value
$3.13B
−$216.3M (−6.5%) vs. Q2 2024
Filed
Nov 14, 2024
SEC
Holdings of Deep Track Capital, LP in Q3 2024
SecurityClassSharesValue% of portfolioShare changeActionHistory
ARGXArgenx SESPONSORED ADR365,000$197.9M6.3%−35,000−8.8%ReducedHistory
DVAXDynavax Technologies CorpCOM NEW12,526,486$139.5M4.5%+1,626,486+14.9%AddedHistory
GHGuardant Health, Inc.COM6,000,560$137.7M4.4%+1,500,560+33.3%AddedHistory
APLSApellis Pharmaceuticals, Inc.COM4,400,654$126.9M4.1%+1,900,654+76.0%AddedHistory
IMVTImmunovant, Inc.COM4,347,464$123.9M4.0%+1,463,728+50.8%AddedHistory
SWTXSpringWorks Therapeutics, Inc.COM3,843,900$123.2M3.9%+143,900+3.9%AddedHistory
DYNDyne Therapeutics, Inc.COM3,282,000$117.9M3.8%−718,000−18.0%ReducedHistory
ITCIIntra-Cellular Therapies, Inc.COM1,600,693$117.1M3.7%+62,771+4.1%AddedHistory
OCULOcular Therapeutix, IncCOM12,721,460$110.7M3.5%00.0%UnchangedHistory
NTLAIntellia Therapeutics, Inc.COM4,950,000$101.7M3.2%+150,000+3.1%AddedHistory
ALKSAlkermes plc.SHS3,500,000$98.0M3.1%00.0%UnchangedHistory
VRNAVerona Pharma plcSPONSORED ADS3,180,025$91.5M2.9%−819,975−20.5%ReducedHistory
IONSIonis Pharmaceuticals IncCOM2,200,000$88.1M2.8%+200,000+10.0%AddedHistory
NRIXNurix Therapeutics, Inc.COM3,868,104$86.9M2.8%−123,396−3.1%ReducedHistory
VRDNViridian Therapeutics, Inc.COM3,750,945$85.3M2.7%−172,904−4.4%ReducedHistory
BCYCBicycle Therapeutics PLCSPONSORED ADS3,548,001$80.3M2.6%+57,495+1.6%AddedHistory
MBXMBX Biosciences, Inc.COM3,018,935$78.4M2.5%+3,018,935NewHistory
AXSMAxsome Therapeutics, Inc.COM857,219$77.0M2.5%−995,565−53.7%ReducedHistory
PLRXPliant Therapeutics, Inc.COM5,972,257$66.9M2.1%00.0%UnchangedHistory
APGEApogee Therapeutics, Inc.COM1,000,000$58.7M1.9%00.0%UnchangedHistory
AUTLAutolus Therapeutics plcSPON ADS15,272,172$55.4M1.8%00.0%UnchangedHistory
GPCRStructure Therapeutics Inc.SPONSORED ADS1,220,508$53.6M1.7%+270,508+28.5%AddedHistory
OLMAOlema Pharmaceuticals, Inc.COM4,000,000$47.8M1.5%00.0%UnchangedHistory
TERNTerns Pharmaceuticals, Inc.COM5,576,558$46.5M1.5%−523,442−8.6%ReducedHistory
FDMT4D Molecular Therapeutics, Inc.COM4,096,452$44.3M1.4%+35,051+0.9%AddedHistory
ABVXAbivax S.A.SPONSORED ADS3,579,209$41.2M1.3%−600,554−14.4%ReducedHistory
TGTXTG Therapeutics, Inc.COM1,725,000$40.3M1.3%−1,145,131−39.9%ReducedHistory
DFTXDefinium Therapeutics, Inc.Stock7,065,099$40.2M1.3%+961,282+15.7%AddedHistory
KURAKura Oncology, Inc.COM1,963,505$38.4M1.2%+1,578,749+410.3%AddedHistory
GERNGeron CorpCOM7,575,049$34.4M1.1%−5,424,951−41.7%ReducedHistory
CYTKCytokinetics IncCOM NEW629,906$33.3M1.1%+497,411+375.4%AddedHistory
ORKAOruka Therapeutics, Inc.COM1,235,187$30.3M1.0%+1,235,187NewHistory
ANIPAni Pharmaceuticals IncCOM504,828$30.1M1.0%+38,739+8.3%AddedHistory
SYRESpyre Therapeutics, Inc.COM NEW1,000,000$29.4M0.9%−756,667−43.1%ReducedHistory
EWTXEdgewise Therapeutics, Inc.COM1,100,536$29.4M0.9%+914,150+490.5%AddedHistory
KYMRKymera Therapeutics, Inc.COM600,326$28.4M0.9%−899,674−60.0%ReducedHistory
KRROKorro Bio, Inc.COM850,000$28.4M0.9%+79,355+10.3%AddedHistory
Avidity Biosciences, Inc.05370A108COM475,000$21.8M0.7%+475,000New–
CNTACentessa Pharmaceuticals plcSPONSORED ADS1,350,000$21.6M0.7%+1,350,000NewHistory
ALECAlector, Inc.COM4,631,998$21.6M0.7%00.0%UnchangedHistory
NKTRNektar TherapeuticsCOM15,922,655$20.7M0.7%−1,952,843−10.9%ReducedHistory
ETNB89bio, Inc.COM2,766,512$20.5M0.7%+472,501+20.6%AddedHistory
BCAXBicara Therapeutics Inc.COM796,852$20.3M0.6%+796,852NewHistory
AKROAkero Therapeutics, Inc.COM689,784$19.8M0.6%+689,784NewHistory
FATEFate Therapeutics IncCOM5,572,607$19.5M0.6%00.0%UnchangedHistory
SLNSilence Therapeutics plcADS1,000,000$18.2M0.6%−359,745−26.5%ReducedHistory
ENGNenGene Therapeutics Inc.COM2,607,633$17.2M0.5%+357,633+15.9%AddedHistory
EDITEditas Medicine, Inc.COM4,900,334$16.7M0.5%−1,099,666−18.3%ReducedHistory
XNCRXencor IncCOM800,000$16.1M0.5%+800,000NewHistory
PYXSPyxis Oncology, Inc.COMMON STOCK4,184,100$15.4M0.5%00.0%UnchangedHistory
CNTXContext Therapeutics Inc.COM7,419,355$14.5M0.5%00.0%UnchangedHistory
HELPCybin Inc.COM NEW1,529,987$13.6M0.4%+1,529,987NewHistory
ZURAZura Bio LtdCLASS A ORD SHS3,283,783$13.3M0.4%00.0%UnchangedHistory
IVVDInvivyd, Inc.COM10,953,937$11.2M0.4%00.0%UnchangedHistory
CLYMClimb Bio, Inc.COM2,169,143$11.0M0.4%−1,735,642−44.4%ReducedHistory
INOInovio Pharmaceuticals, Inc.COM SHS1,804,366$10.4M0.3%−262,354−12.7%ReducedHistory
AVTXAvalo Therapeutics, Inc.COM NEW967,000$9.19M0.3%+967,000NewHistory
NMRANeumora Therapeutics, Inc.COM567,428$7.50M0.2%+567,428NewHistory
TVTXTravere Therapeutics, Inc.COM531,857$7.44M0.2%−6,838,143−92.8%ReducedHistory
VIGLVigil Neuroscience, Inc.COM1,553,996$5.28M0.2%+956,781+160.2%AddedHistory
RGLSRegulus Therapeutics Inc.COM3,262,564$5.12M0.2%00.0%UnchangedHistory
ALLKAllakos Inc.COM5,000,000$3.27M0.1%00.0%UnchangedHistory
ANROAlto Neuroscience, Inc.COM SHS219,648$2.51M0.1%−292,038−57.1%ReducedHistory
PRTAProthena Corp Public Ltd CoSHS140,000$2.34M0.1%+140,000NewHistory
RLMDRelmada Therapeutics, Inc.COM674,833$2.19M0.1%−559,940−45.3%ReducedHistory
ALGSAligos Therapeutics, Inc.COM NEW244,110$2.11M0.1%00.0%UnchangedConverted for a 1-for-25 splitHistory
SYRSSyros Pharmaceuticals, Inc.COM NEW828,485$1.78M0.1%00.0%UnchangedHistory
MGXMetagenomi Therapeutics, Inc.COM307,500$667.3K<0.1%−158,732−34.0%ReducedHistory
SRRKScholar Rock Holding CorpCOM48,100$385.3K<0.1%−324,459−87.1%ReducedHistory

Options (2)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Deep Track Capital, LP in Q3 2024
SecurityClassPutsCalls
AXSMAxsome Therapeutics, Inc.COM–$18.0M
NMRANeumora Therapeutics, Inc.COM–$2.38M

Sold out since Q2 2024 (9)

Positions held at the end of Q2 2024 that are gone from this filing.

Positions of Deep Track Capital, LP sold out since Q2 2024
SecurityClassShares in Q2 2024Value in Q2 2024% of portfolio in Q2 2024History
AMGNAmgen IncStock575,000$179.7M5.4%History
INSMINSMED IncCOM PAR $.012,000,000$134.0M4.0%History
ALNYAlnylam Pharmaceuticals, Inc.COM500,000$121.5M3.6%History
HLVXHilleVax, Inc.COM1,832,652$26.5M0.8%History
PRAXPraxis Precision Medicines, Inc.COM NEW389,546$16.1M0.5%History
Cybin Ord23256X100COM58,139,535$15.8M0.5%–
AGENAgenus IncCOM NEW313,359$5.25M0.2%History
RPTXRepare Therapeutics Inc.COM904,261$2.98M0.1%History
COGTCogent Biosciences, Inc.COM308,235$2.60M0.1%History